Wednesday, August 26, 2026
ExploreSearch
Via News
Via News Knowledge File

Sanofi

organization80% conf.·synced Aug 19, 2026

Pharmaceutical company partnered with Teva for duvakitug additional indications

22
sourced metrics
805
relationships
20
stated objectives
2
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Market Cap
54837636507USD
Aug 18, 2026reference only
Stock Return Ytd
-6.8%
Aug 18, 2026reference only
Stock Price
44.97USD
Aug 18, 2026reference only
Price 52 Week Low
41.33USD
Aug 18, 2026reference only
Price 52 Week High
52.34USD
Aug 18, 2026reference only
Margin
-68.7percent
Apr 1, 2026source
Eps
4.97USD
Mar 3, 2026⚠ sources conflictsource
Rare Disease Experience
40years
Feb 2, 2026source
Rare Disease Commitment
40years
Feb 2, 2026source
Collaboration Revenue
5.9billion_USD
Jan 30, 2026⚠ sources conflictsource
Cash
877000000.0USD
Dec 31, 2025reference only
Total Assets
126805000000.0USD
Dec 31, 2025reference only
Gross Profit
33667000000.0USD
Dec 31, 2025reference only
Rd Expense
7842000000.0USD
Dec 31, 2025reference only
Shares Outstanding
1219427096.0shares
Dec 31, 2025reference only
Acquisition Price Per Share
15.50USD
Dec 24, 2025source
China Approvals 2025
5approvals
Dec 11, 2025source
China Drug Approvals 2025
5approvals
Dec 11, 2025source

Stated objectives

Advance Dynavax's shingles vaccine candidate (Z-1018) through clinical development

source
stated

Augment Sanofi's presence in adult immunization by combining Dynavax's vaccines with Sanofi's global scale, development capabilities and commercial reach

source
stated

Provide vaccine protection across the lifespan through differentiated vaccine portfolio

source
stated

Submit global regulatory submissions for amlitelimab

source
stated

Report results from AQUA and ESTUARY phase 3 studies

source
stated

Study dupilumab in chronic pruritus of unknown origin, lichen simplex chronicus, and allergic fungal rhinosinusitis in phase 3 studies

source
stated

Complete global regulatory submissions for amlitelimab

source
stated

Publish results from AQUA and ESTUARY phase 3 studies

source
stated

Present COAST 1, COAST 2, SHORE and ATLANTIS results at upcoming medical conferences

source
stated

Study dupilumab in phase 3 trials for chronic pruritus of unknown origin, chronic lichen simplex, and allergic fungal rhinosinusitis

source
stated

Relationship graph · 805 connections

Employs
237
Developed by
141
regulates
88
Competes with
72
headquartered in
61
regulated by
19
researched at
18
Owns
16
headquartered in
Paris

Via News coverage

GSK's Depemokimab Targets Late 2027 Launch: What Investors Need to Know About the Ultra-Long-Acting Biologic Bet
February 18, 2026
FDA Delays Review of Moderna's Influenza Vaccine Application
February 11, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com